Intesa Sanpaolo Turns to Gemalto for Italy’s First Biometric Contactless Payment Card Pilot
Gemalto, the leader in digital security, is supplying Intesa Sanpaolo,
the number one banking group in ltaly, with the first Mastercard biometric
contactless payment card.
The pilot promoted by Intesa Sanpaolo
and Mastercard allows to test an EMV contactless biometric card for the
first time in Europe. Consumers may simply tap their card to any POS
terminal to pay and authorize the transaction with their fingerprint,
combining a fast and convenient user experience to an advanced
cardholder authentication approach. In addition, the card works without
a battery as it’s powered by the terminal which means that there is no
limit on the number of transactions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005481/en/
Biometric payment card (Photo: Gemalto)
Enhanced contactless payment working with existing infrastructure
Intesa Sanpaolo’s initiative is the latest step forward in the bank’s
ambitious digital transformation strategy. Fingerprint authentication
sweeps away limits on the value of contactless
payments, removing the need to enter a PIN or sign the receipt, As a
result, it simplifies the consumer experience at the point of sale and
makes it faster and safer.
The card works with existing EMV card
terminal infrastructure, so merchants can easily maximize the shopping
experience delivered to their customers without the need to upgrade
their current hardware or software. For issuers, the technology helps
detect and prevent fraud, increase approval rates, reduce operational
costs and foster customer loyalty.
Fully secure, on-the spot fingerprint enrollment
Intesa Sanpaolo has 11.9 million customers and 4,400 branches in Italy. Gemalto’s solution includes secure on-the-spot fingerprint enrollment at selected locations and in the future customers could even enroll for the service at home. To ensure the right to privacy, biometric data is stored on the card itself, not the bank’s servers. Protection is further enhanced by the fact that personal data is encrypted and never leaves the card.
“We are proud to have undertaken the first step to introduce in Italy a card which technology offers the consumers clear and concrete benefits, following our choice to anticipate and facilitate the diffusion of innovative technologies functional to people's everyday banking.” said Cinzia Bruzzone, Retail Manager Intesa Sanpaolo. “The Intesa Sanpaolo - Mastercard pilot project, achieved with Mercury Payment System support, avails itself of Gemalto's contribution as a global operator, who provided the technology behind the new biometric cards and the tools necessary for storing the fingerprint on the chip.”
“Consumers are quickly recognizing the combined power of contactless and biometric technologies to take the stress and strain out of secure transactions,” said Bertrand Knopf, executive vice president Banking and Payment for Gemalto. “We are delighted to work with Intesa Sanpaolo and Mastercard on another pioneering project, this time bringing the effortless safety of a biometric sensor EMV card to their consumers.”
Intesa Sanpaolo’s initial pilot will run in Turin, Milan and Rome and is scheduled to last 16 weeks.
About Gemalto
Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security, with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.
From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.
Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.
For more information visit www.gemalto.com, or follow @gemalto on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181218005481/en/
Contact information
Gemalto media:
Tauri Cox
North America
+1 512 257
3916
tauri.cox@gemalto.com
Sophie Dombres
Europe Middle East & Africa
+33 4 42 36 57
38
sophie.dombres@gemalto.com
Piyush Prakash
Asia Pacific
+91 11 6623 1200
piyush.prakash@gemalto.com
Alexis Camarillo
Latin America
+52 5521223627
alexis.camarillo@gemalto.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new